Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01824303 · ClinicalTrials.gov registry record · Phase 2
Safety, Tolerability and Efficacy Study of LiRIS® 400 mg in Women With Interstitial Cystitis
A Phase 2 study, sponsored by Allergan.
- Terminated
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
NCT01824303 is a Phase 2 study that was terminated before completion, run by Allergan. The registered enrollment target is 31 participants.
The verdict
NCT01824303, a Phase 2 study, was terminated before completion, sponsored by Allergan.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
Study Summary
The purposes of the study is to determine if LiRIS®, an investigational drug-delivery system, is safe and tolerable in women with Interstitial Cystitis (IC), and to evaluate any change in IC symptoms following LiRIS administration.
Interventions
- DRUG LiRIS 400 mg
- OTHER LiRIS Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2013-03 |
| Est. Completion | 2014-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01824303
The ClinicalTrials.gov registry entry for NCT01824303 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which LiRIS 400 mg is the first listed.
NCT01824303 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01824303 about?
NCT01824303 is a clinical study titled "Safety, Tolerability and Efficacy Study of LiRIS® 400 mg in Women With Interstitial Cystitis". The purposes of the study is to determine if LiRIS®, an investigational drug-delivery system, is safe and tolerable in women with Interstitial Cystitis (IC), and to evaluate any change in IC symptoms following LiRIS administration.
What is the current status of trial NCT01824303?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2013-03. Estimated completion is 2014-12.
What interventions are being tested in trial NCT01824303?
The interventions under investigation include: LiRIS 400 mg (DRUG), LiRIS Placebo (OTHER).
Who is sponsoring clinical trial NCT01824303?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.